1. Cancer Biology

Arginase 1 is a key driver of immune suppression in pancreatic cancer

  1. Rosa E Menjivar
  2. Zeribe C Nwosu
  3. Wenting Du
  4. Katelyn L Donahue
  5. Hanna S Hong
  6. Carlos Espinoza
  7. Kristee Brown
  8. Ashley Velez-Delgado
  9. Wei Yan
  10. Fatima Lima
  11. Allison Bischoff
  12. Padma Kadiyala
  13. Daniel Salas-Escabillas
  14. Howard C Crawford
  15. Filip Bednar
  16. Eileen Carpenter
  17. Yaqing Zhang
  18. Christopher J Halbrook
  19. Costas A Lyssiotis  Is a corresponding author
  20. Marina Pasca di Magliano  Is a corresponding author
  1. Cellular and Molecular Biology Program, University of Michigan-Ann Arbor, United States
  2. Department of Molecular and Integrative Physiology, University of Michigan-Ann Arbor, United States
  3. Department of Surgery, University of Michigan-Ann Arbor, United States
  4. Cancer Biology Program, University of Michigan-Ann Arbor, United States
  5. Department of Immunology, University of Michigan-Ann Arbor, United States
  6. Department of Cell and Developmental Biology, University of Michigan-Ann Arbor, United States
  7. Henry Ford Pancreatic Cancer Center, United States
  8. Rogel Cancer Center, United States
  9. Department of Internal Medicine, Division of Gastroenterolog, University of Michigan-Ann Arbor, United States
  10. Department of Molecular Biology and Biochemistry, University of California, Irvine, United States
  11. Chao Family Comprehensive Cancer Center, University of California, Irvine, United States
https://doi.org/10.7554/eLife.80721
Share this article
Cite this article
  1. Rosa E Menjivar
  2. Zeribe C Nwosu
  3. Wenting Du
  4. Katelyn L Donahue
  5. Hanna S Hong
  6. Carlos Espinoza
  7. Kristee Brown
  8. Ashley Velez-Delgado
  9. Wei Yan
  10. Fatima Lima
  11. Allison Bischoff
  12. Padma Kadiyala
  13. Daniel Salas-Escabillas
  14. Howard C Crawford
  15. Filip Bednar
  16. Eileen Carpenter
  17. Yaqing Zhang
  18. Christopher J Halbrook
  19. Costas A Lyssiotis
  20. Marina Pasca di Magliano
(2023)
Arginase 1 is a key driver of immune suppression in pancreatic cancer
eLife 12:e80721.
https://doi.org/10.7554/eLife.80721
  2. Download BibTeX
  3. Download .RIS

Abstract

An extensive fibroinflammatory stroma rich in macrophages is a hallmark of pancreatic cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and contribute to the poor response to immunotherapy; however, the mechanisms of immune suppression are complex and not fully understood. Immunosuppressive macrophages are classically defined by the expression of the enzyme Arginase 1 (ARG1), which we demonstrated is potently expressed in pancreatic tumor-associated macrophages from both human patients and mouse models. While routinely used as a polarization marker, ARG1 also catabolizes arginine, an amino acid required for T cell activation and proliferation. To investigate this metabolic function, we used a genetic and a pharmacologic approach to target Arg1 in pancreatic cancer. Genetic inactivation of Arg1 in macrophages, using a dual recombinase genetically engineered mouse model of pancreatic cancer, delayed formation of invasive disease, while increasing CD8+ T cell infiltration. Additionally, Arg1 deletion induced compensatory mechanisms, including Arg1 overexpression in epithelial cells, namely Tuft cells, and Arg2 overexpression in a subset of macrophages. To overcome these compensatory mechanisms, we used a pharmacological approach to inhibit arginase. Treatment of established tumors with the arginase inhibitor CB-1158 exhibited further increased CD8+ T cell infiltration, beyond that seen with the macrophage-specific knockout, and sensitized the tumors to anti-PD1 immune checkpoint blockade. Our data demonstrate that Arg1 drives immune suppression in pancreatic cancer by depleting arginine and inhibiting T cell activation.

Editor's evaluation

Menjivar et al. identify an important, previously unrecognized role of myeloid cell Arginase1 (Arg1) activity in shaping the anti-tumor immune response in pancreatic ductal adenocarcinoma (PDAC). The proposed therapeutic combination is a convincing new approach for pancreatic cancer, with an enhanced response to immune therapy upon arginase inhibition.

https://doi.org/10.7554/eLife.80721.sa0

Introduction

Pancreatic ductal adenocarcinoma (PDA) is currently the third leading cause of cancer-related deaths in the United States with a 5-y survival rate of 12% (Siegel et al., 2023). This poor survival rate is due to late detection and ineffective treatments. The hallmark mutation in PDA is found in the KRAS gene, most commonly KRASG12D (Hezel et al., 2006; Hingorani et al., 2003; Hingorani et al., 2005; Schneider and Schmid, 2003), whereas disease progression is accelerated by loss of tumor suppressor genes, including TP53, SMAD4, and INK4A (Hezel et al., 2006; Maitra and Hruban, 2008).

Standard of care for PDA is a combination of systemic chemotherapy that includes FOLFIRINOX or gemcitabine plus nab-paclitaxel (Mizrahi et al., 2020), which provides limited improvement in patient survival. Oncogenic KRAS proteins were long thought to be ‘undruggable’ (Gysin et al., 2011; Liu et al., 2019). Recently, new approaches to drug discovery have led to the development of KRASG12C inhibitors (Canon et al., 2019; Fell et al., 2020), a common mutation in non-small cell lung cancer (Prior et al., 2012); initial clinical data show not only dramatic responses but also cases of primary or secondary resistance (Awad et al., 2021). While the applicability of G12C inhibitors is limited in PDA, which is rarely present with this specific allele (Witkiewicz et al., 2015), new KRASG12D inhibitors have recently been described and are entering the clinic (Hallin et al., 2022; Wang et al., 2022). Based on the observations in lung cancer (Awad et al., 2021; Zhao et al., 2021) and on predictions based on mouse models that allow genetic inactivation of oncogenic KRAS (Collins et al., 2012; Ying et al., 2012), it is to be expected that resistance to KRAS G12D inhibitors will similarly arise; activation of anti-tumor immune responses remains our best hope for long-term tumor control. Although immune checkpoint inhibitors are effective in other cancers, this benefit has not translated to PDA (Brahmer et al., 2012; Royal et al., 2010) due to the severely immunosuppressive tumor microenvironment (TME) that characterizes this disease (Morrison et al., 2018; Vonderheide and Bayne, 2013). Approaches combining immune checkpoints and myeloid cell targeting might be more promising, based on preclinical studies (DeNardo et al., 2021; Gulhati et al., 2023; Liu et al., 2021). Here, we explore new approaches targeting macrophages to induce anti-tumor immunity in pancreatic cancer.

The pancreatic TME includes cancer-associated fibroblasts and a heterogenous population of immune cells, the majority of which is myeloid cells (Gabrilovich and Nagaraj, 2009). These myeloid cells include tumor-associated macrophages (TAMs), immature myeloid cells, also referred to as myeloid-derived suppressor cells, and granulocytes, such as neutrophils (Gabrilovich et al., 2012). In contrast, CD8+ T cells are rare in the pancreatic TME, although their prevalence is heterogeneous in different patients (Stromnes et al., 2017). Single-cell RNA sequencing (sc-RNA-seq) analysis revealed that most CD8+ T cells infiltrating PDA have an exhausted phenotype (Steele et al., 2020). An understanding of the mechanisms mediating immune suppression in pancreatic cancer is needed to design new therapeutic approaches for this disease. Of note, analysis of long-term survivors revealed persistence of tumor-specific memory CD8+ T cells, indicating that when an anti-tumor immune response does occur, it leads to effective tumor control (Balachandran et al., 2017). Conversely, evidence of loss of antigens over time due to immunoediting has also been described (Łuksza et al., 2022). Furthermore, myeloid cell depletion in mouse models of pancreatic cancer led to activation of anti-tumor T cell responses (Mitchem et al., 2013; Zhang et al., 2017a), spurring an effort to target myeloid cells in pancreatic cancer (Nywening et al., 2016); yet, clinical efficacy has been low, and more effective approaches are needed.

Myeloid cells infiltrating the neoplastic pancreas, and ultimately those in PDA, express high levels of Arginase 1 (Arg1). ARG1 is one of the enzymes that metabolize arginine, and it is prevalently located in the cytoplasm, while the ARG2 isoform is prevalently mitochondrial (Bronte and Zanovello, 2005). Indeed, we previously showed that Arg1 expression in myeloid cells is driven by oncogenic Kras expression/signaling in epithelial cells, starting during early stages of carcinogenesis (Velez-Delgado et al., 2022; Zhang et al., 2017b). Beyond our work, ARG1 is widely appreciated as a marker of alternatively polarized macrophages. An increase in tumor myeloid Arg1 expression has been reported in other cancers, including renal cell carcinoma (Rodriguez et al., 2009), breast (Polat et al., 2003; Singh et al., 2000), colon (Arlauckas et al., 2018), and lung cancer (Miret et al., 2019).

In addition to its role as a marker of alternatively polarized macrophages, ARG1 is a metabolic enzyme that breaks down the amino acid L-arginine to urea and ornithine (Jenkinson et al., 1996). Connecting this activity to myeloid Arg1 expression, several reports detail how arginine is necessary for the activation and proliferation of CD8 T cells (Rodriguez et al., 2007; Rodriguez et al., 2004). This indicates that myeloid cells may deplete arginine in the TME to dampen anti-tumor T cell activity. Based on these concepts, a small-molecule arginase inhibitor, CB-1158 (INCB001158) (Calithera Biosciences, Inc, South San Francisco, CA), was developed. CB-1158 treatment as monotherapy, or in combination with anti-PD-1 checkpoint inhibitor, decreased tumor growth in vivo in mice with Lewis lung carcinoma (Steggerda et al., 2017). CB-1158 also inhibits human arginase, and it is being tested in a phase I clinical trial in patients with advanced or metastatic solid tumors (Pham et al., 2018; Steggerda et al., 2017).

Encouraged by these studies and the prominent disease-specific expression of Arg1 in PDA macrophages, we set forth to determine its functional role. Here, we used a dual-recombinase approach to delete Arg1 in myeloid cell lineages via Cre-loxP technology and at the same time induced oncogenic Kras in pancreatic epithelial cells using the orthogonal Flp-Frt recombination approach. We discovered that Arg1 deletion in myeloid cells profoundly reshaped the TME, increased the infiltration of CD8+ T cells, and reduced malignant disease progression. However, we also noticed a resistance mechanism whereby other cells in the TME, such as epithelial cells, upregulate Arg1 expression, potentially blunting the effect of its inactivation in myeloid cells. We thus employed a systemic approach, whereby we treated a syngeneic orthotopic model of pancreatic cancer with the arginase inhibitor CB-1158 and found it to sensitize PDA to anti-PD1 immune checkpoint blockade. These results illustrate a functional role of Arg1 in pancreatic tumor-derived myeloid cells, reveal novel aspects of intratumoral compensatory metabolism, and provide new inroads to increase the efficacy of checkpoint immune therapy for PDA.

Results

Pancreatic cancer infiltrating myeloid cells express Arginase 1

We have previously reported that expression of oncogenic Kras in pancreas epithelial cells drives expression of Arg1 in macrophages in vivo during early stages of carcinogenesis (Velez-Delgado et al., 2022; Zhang et al., 2017b). We sought to determine whether Arg1 was also associated with late stages of carcinogenesis in mouse and human tumors. As there was no validated antibody for human ARG1 available, we performed ARG1 RNA in situ hybridization in human PDA, together with co-immunofluorescence staining for the immune cell marker CD45 and for the epithelial cell marker E-cadherin (ECAD) (Figure 1A). We observed prevalent ARG1 expression in CD45+ cells, and occasional low expression in ECAD+ cells (Figure 1A, Figure 1B). Analysis of a previously published sc-RNA-seq dataset, which includes 16 human PDA samples (Steele et al., 2020; Figure 1C and Figure 1—figure supplement 1A), revealed highest expression of ARG1 in myeloid cells (Figure 1D, Figure 1—figure supplement 1B). In contrast, we observed minimal ARG1 expression in CD4+ T cells, CD8+ T cells, epithelial cells, and fibroblasts (Figure 1D). ARG2 was expressed at high levels in endocrine cells, and at lower, but detectable levels in epithelial cells (Figure 1—figure supplement 1B). Thus, we conclude that myeloid cells are the main source of ARG1 in the pancreatic cancer microenvironment.

Figure 1 with 1 supplement see all
Download asset Open asset
Arginase 1 (Arg1) is highly expressed in human and mouse myeloid cells.

(A) Representative image of RNA in situ hybridization (ISH) of ARG1 (red) and co-immunofluorescence staining of immune (CD45, green) and epithelial (E-cadherin [ECAD], magenta) cells in human pancreatic ductal adenocarcinoma (PDA). Counterstain, DAPI (blue). White arrows point to ARG1-ISH in ECAD+ cells, and yellow arrows point to ARG1-ISH in CD45+ cells. Scale bar, 50 μm. (B) Quantification of average ARG1+ puncta in CK19 and CD45 cells. Unpaired t test with Welch’s correction was used to determine statistical significance. (C) Uniform manifold approximation and projection (UMAP) visualization of 13 identified cell populations from single-cell RNA sequencing (sc-RNA-seq) of 16 human PDA tumors. Data from Steele et al., 2020. (D) Violin plot of normalized gene expression of ARG1 in the identified cell populations from the human PDA sc-RNA-seq. (E) Survival analysis of a human PDA microarray data set (GSE71729) with low (n=62) and high (n=63) ARG1 expression. Statistical significance was determined using the Kaplan Meier overall survival Logrank test. (F) UMAP visualization of 11 identified populations from healthy and PDA merged mouse sc-RNA-seq. (G) Violin plot of normalized gene expression of Arg1 in the identified cell populations from mouse sc-RNA-seq. (H) Representative co-immunofluorescence staining for ARG1 (red), macrophages (F4/80, green), and epithelial (ECAD, blue) cells in mouse tissue at different stages of disease. Counterstain, DAPI (gray). Scale bar, 50 μm. Yellow arrows indicate ARG1 expression in F4/80+ cells. (I) Quantification of F4/80+ ARG1+ cells in healthy, PanIN, and PDA mouse tissue. Statistical significance was determined using an ordinary one-way ANOVA with multiple comparisons. p Value was considered statistically significant when p<0.05.

Infiltration of myeloid cells, specifically macrophages, in pancreatic cancer portends worse patient survival (Sanford et al., 2013; Tsujikawa et al., 2017). We thus assessed whether ARG1 expression correlated with worse patient outcomes. Based on a publicly available human PDA microarray data set (GSE71729) (Moffitt et al., 2015), we found that high ARG1 expression in pancreatic cancer correlated with worse survival (Figure 1E), suggesting that ARG1 in myeloid cells may play a functional role in human PDA.

Next, to determine whether the increase in Arg1 expression was recapitulated in a mouse model of pancreatic cancer, we analyzed our mouse sc-RNA-seq data from healthy mice and tumor-bearing KPC (KrasLSL-G12D/+;p53LSL-R172H/+;Ptf1aCre/+) (Hingorani et al., 2005) mice (Figure 1F and Figure 1—figure supplement 1C and D). We detected the highest level of Arg1 expression in macrophages (Figure 1G and Figure 1—figure supplement 1E). Importantly, Arg1 expression was enriched in PDA infiltrating macrophages compared to macrophages in the normal pancreas (Figure 1G and Figure 1—figure supplement 1E). Other cell types, such as epithelial cells and fibroblasts, only had sporadic Arg1 expression. Arg2 was also expressed in macrophages, albeit at low levels, and was the prevalent isoform in tumor-associated granulocytes (Figure 1—figure supplement 1E). To evaluate the protein expression of ARG1, we performed co-immunofluorescence staining. We included healthy pancreas samples, PanIN-bearing pancreata from KC mice (KrasLSL-G12D/+;Ptf1aCre/+) (Hingorani et al., 2003), and PDA. We did not detect ARG1 protein in the healthy pancreas. In contrast, both PanIN and PDA presented with frequent co-localization of the macrophage marker F4/80 with ARG1, consistent with prevalent expression in this cell population (Figure 1H and I and Figure 1—figure supplement 1F). Consistent with human data, expression of ARG1 in other cell types was rare (Figure 1H and Figure 1—figure supplement 1F). Thus, both in mouse and human pancreatic cancer, ARG1 is highly expressed and largely confined to tumors, where it is predominantly expressed in macrophages.

Arginase 1 deletion in myeloid cells reduces tumor progression and induces macrophage repolarization

To examine the function of myeloid Arg1 in PDA, we generated mice lacking Arg1 expression in myeloid cells. Specifically, we crossed Arg1f/f mice with Lyz2Cre/+ mice to generate Lyz2Cre/+;Arg1f/f mice (El Kasmi et al., 2008). Lyz2Cre/+ mice were generated by inserting the Cre cDNA in the endogenous M lysozyme (LysM) locus (Clausen et al., 1999), which is broadly expressed in myeloid cells, including macrophages and neutrophils (Clausen et al., 1999; El Kasmi et al., 2008). To validate the deletion of Arg1 in macrophages, we harvested bone marrow (BM) cells from wild type (WT) or Lyz2Cre/+;Arg1f/f mice and cultured these directly in pancreatic cancer cell conditioned media (CM) for 6 d. This protocol yields BM-derived TAMs (Figure 2A), as previously described (Zhang et al., 2017a). ARG1 expression was readily detectable in WT TAMs; in contrast, Lyz2Cre/+;Arg1f/f TAMs had none or very low ARG1 protein, indicating efficient Cre recombination (Figure 2B). We then sought to determine whether ARG1 expression in TAMs affected the metabolite composition of the media. We thus performed extracellular metabolomics by liquid chromatography couple tandem mass spectrometry (LC-MS/MS) and observed elevated levels of L-Arginine in the Lyz2Cre/+;Arg1f/f TAM medium compared with WT TAM medium (Figure 2C). This finding is consistent with WT TAMs depleting arginine from their growth medium at an enhanced rate, relative to TAMs lacking Arg1 expression.

Figure 2 with 3 supplements see all
Download asset Open asset
Arginase 1 (Arg1) deletion in myeloid cells reduces tumor progression and induces macrophage repolarization in a spontaneous pancreatic ductal adenocarcinoma (PDA) mouse model.

(A) Schematic illustration for the generation of tumor-associated macrophages (TAMs) from wild-type (WT) and Lyz2Cre/+;Arg1f/f mice. (B) Representative image of western blot for ARG1 levels in WT and Lyz2Cre/+;Arg1f/f TAMs. Vinculin, loading control. (C) Heatmap of statistically significantly different extracellular metabolites from WT (lanes 1–4) and Lyz2Cre/+;Arg1f/f (lanes 5–8) TAM media. (D) Genetic makeup of the KrasFrt-STOP-Frt-G12D/+;Ptf1aFlpO/+;Lyz2Cre/+;Arg1f/f (KFCA) mouse model for the deletion of Arg1 in myeloid cells during PDA tumorigenesis. Data shown here from mice aged 9–16 mo, n=24–26/group. (E) Representative hematoxylin and eosin (H&E) staining from age matching KF and KFCA mice. Scale bar, 100 μm. Histopathology evaluation shown on the right (n=26 KF and 24 KFCA, age matched, 9–16 mo old). Statistical significance was determined using chi-square test. Statistically significant when P<0.05. (F) Representative image of co-immunofluorescence staining for ARG1 (red), macrophages (F4/80, green), epithelial (CK19, gray), and DAPI (blue) in KF and KFCA tissue. Scale bar, 50 μm. Quantification on the right, n=5–6/group. Significance was determined using unpaired t test with Welch’s correction. Statistically significant when p<0.05. (G) Uniform manifold approximation and projection (UMAP) visualization for the identified cell populations in merged KF and KFCA single-cell RNA sequencing. (H) Heatmap of top differentially expressed genes in the macrophage subclusters identified from KF and KFCA pancreata. (I) Dot plot visualization of Arg1 and Arg2 expression in KF and KFCA macrophage clusters. Average expression is shown by color intensity and expression frequency by dot size. (J) Reactome pathway enrichment analysis showing significantly upregulated pathways in KFCA macrophages.

Figure 2—source data 1

Full membrane scan for the western blot in Figure 2B.

Vinculin is the loading control, 124 kDa. ARG1 is 40 kDa.

https://cdn.elifesciences.org/articles/80721/elife-80721-fig2-data1-v2.zip

To investigate the function of Arg1 in myeloid cells during PDA progression, we generated KrasFrt-STOP-Frt-G12D/+;Ptf1aFlpO/+ (KF); Lyz2Cre/+;Arg1f/f mice, hereafter referred to as KFCA (Figure 2D and Figure 2—figure supplement 1A). The dual-recombinase system integrates both Flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies to independently modify epithelial cells and myeloid cells (Garcia et al., 2020; Wen et al., 2019). We aged a cohort of KF and KFCA mice for 2 mo, a timepoint at which PanIN lesions are formed in KF mice (Figure 2—figure supplement 1A). To evaluate the efficiency of Arg1 deletion, we performed co-immunofluorescent staining for ARG1, F4/80, and CK19. As expected, we observed abundant expression of ARG1 in F4/80+ macrophages in KF, and minimal to no expression of ARG1 in macrophages from KFCA tissue (Figure 2—figure supplement 1B). We then performed histopathological evaluation of the tissue to determine the functional effect of loss of myeloid Arg1. Here, we observed a trending decrease in ADM and PanIN lesions (although not statistically significant), accompanied by a reduction of desmoplastic stroma in KFCA, compared to age-matched KF pancreata (Figure 2—figure supplement 1C).

To investigate the causes underlying the trending reduction in PanIN formation, we performed an in-depth histological analysis. We previously showed that macrophages can directly promote epithelial cell proliferation during early stages in carcinogenesis (Zhang et al., 2017b). We and others have also demonstrated that macrophages also indirectly promote carcinogenesis by suppressing CD8+ T cell infiltration and activation (Bayne et al., 2012; Mitchem et al., 2013; Pylayeva-Gupta et al., 2012; Zhang et al., 2017a; Zhu et al., 2017). Immunostaining for the proliferation marker Ki67 revealed a reduction in total cell proliferation, and a reduction in cell death as determined by cleaved caspase-3 (CC3) staining (Figure 2—figure supplement 1D). Immunofluorescence staining for immune cells by CD45 did not reveal changes in total CD45+ cells (Figure 2—figure supplement 1E). Similarly, we did not find changes in infiltrating F4/80+ macrophages or CD8+ T cells by immunohistochemistry staining (Figure 2—figure supplement 1F). Thus, loss of Arg1 in macrophages appears to reduce the ability of macrophages to promote proliferation but, at this stage, does not appear to correlate with changes in the immune system. These findings are consistent with our previous observations on the role of macrophages during the onset of carcinogenesis (Zhang et al., 2017b).

Given the trending reduction in PanIN formation, we next investigated the effects of myeloid Arg1 deletion on progression to PDA. For this purpose, we aged KF and KFCA mice to 9–16 mo (Figure 2D), an age where we have previously observed invasive cancer formation in KF mice (Garcia et al., 2020). Accordingly, 16 out of 26 KF mice (62%) had invasive disease; in contrast, only 5 out of 24 KFCA mice had progressed (21%) (Figure 2E). We then stained the tissue for ARG1 together with F4/80, and CK19. As expected, we observed high ARG1 expression in macrophages in KF tissues and little to no ARG1 expression in macrophages in KFCA pancreata (Figure 2F). Surprisingly, we observed substantial ARG1 expression in epithelial cells from the KFCA pancreata, while epithelial cells in KF mice had little to no ARG1 expression (Figure 2F and Figure 2—figure supplement 2A). So, while deletion of Arg1 in myeloid cells impairs malignant progression, it unleashes a compensatory upregulation of Arg1 in epithelial cells.

We noted that the epithelia that expressed ARG1 in KFCA mice had an elongated appearance, consistent with tuft cells, a cell type that is not present in the healthy pancreas but common in low-grade PanINs (Delgiorno et al., 2014). By co-immunostaining for the tuft cell marker COX1, we confirmed that tuft cells are the exclusive source of epithelial ARG1 in these samples (Figure 2—figure supplement 2A), suggesting a tuft cell response to accumulating arginine in the microenvironment.

To comprehensively characterize the phenotype of myeloid Arg1 deleted mice, we performed sc-RNA-seq on KF (n=1) and KFCA (n=1) pancreata dissected from 11 mo old mice. Unsupervised clustering identified abundant stromal and immune cells, and a small population of epithelial cells, in both genotypes (Figure 2G and Figure 2—figure supplement 2B and C). The percentage of total macrophages was similar between KF and KFCA pancreas (Figure 2—figure supplement 2D and E, Figure 2—figure supplement 3A and B). We then subclustered the macrophages, from which we identified five different macrophage populations based on distinct gene profiles (Figure 2H and Figure 2—figure supplement 3C). The macrophage 1 population was defined by Apoe, C1qa, and C1qc markers of TAMs in mouse and human pancreatic cancer (Kemp et al., 2021a), while the macrophage 5 population expressed Ear2 and Retnla (Figure 2H). Since macrophage APOE (Apolipoprotein E) is tumor promoting (Kemp et al., 2021a), we performed co-immunofluorescent staining for APOE, F4/80, and ECAD and detected a reduction in APOE expression (Figure 2—figure supplement 3D and E). scRNA-seq identified Apoe expression mainly in the KF macrophage 1 population with reduced expression in the KFCA population (Figure 2—figure supplement 3F).

Intriguingly, sc-RNA-seq revealed that deletion of Arg1 in myeloid cells led to an upregulation of Arg2 expression, mainly in the macrophage 4 population expressing Chil3, Ly6c2, and Clec4e genes (Figure 2I), suggesting the existence of a compensatory mechanism. We then performed reactome pathway enrichment analysis on the macrophage sc-RNA-seq data to determine both up- and down-regulated pathways (Figure 2J and Figure 2—figure supplement 3G). Interestingly, KFCA macrophages, mainly the macrophage 3 population, exhibited upregulation of signaling pathways involved in MHC I antigen processing and cross presentation (Figure 2J and Figure 2—figure supplement 3H), suggesting an improvement in antigen-specific CD8+ T cell activation upon Arg1 deletion. Among the differentially expressed genes in MHC I-mediated antigen processing and presentation were H2-K1, Psmb8, H2-Q7, Ubb, H2-T23, Psmb9, H2-T22, Uba52, H2-Q6, Mrc1, Rbx1, Psmd8, Psmb5, and Znrf2 (Figure 2—figure supplement 3H).

Deletion of Arginase 1 in myeloid cells increases CD8+ T cell infiltration and activation

Macrophages in pancreatic cancer are highly immunosuppressive and have defective antigen presentation (DeNardo and Ruffell, 2019). As sc-RNA-seq suggested that Arg1 null macrophages have higher antigen presenting activity, we stained KF and KFCA pancreata for CD8 and observed increased CD8+ T cell infiltration in the latter (Figure 3A). We then sub-clustered T and natural killer (NK) cells in the sc-RNA-seq datasets from KF and KFCA pancreata and classified these into the following subclusters: naïve CD8+ T cells, cytotoxic CD8+ T cells, exhausted CD8+ T cells, CD4+ T cells, regulatory T cells (Treg), γδ T cells, NKT, and NK cells (Figure 3B and C). From this analysis, we observed an increase in the percentage of both cytotoxic and exhausted CD8+ T cells in the KFCA model compared with KF (Figure 3D and E). Correspondingly, expression of genes related to CD8+ T cell cytotoxicity, including Granzyme b (Gzmb), Perforin 1 (Prfn1), and Interferon gamma (Ifng) was upregulated in CD8+ T cells from the KFCA model (Figure 3F). Accordingly, co-immunofluorescent staining for CD8, GZMB, and ECAD showed an increase in GZMB-expressing CD8+ T cells in KFCA pancreata (Figure 3G and H). We also found that the expression of genes involved in T cell exhaustion such as cytotoxic T-lymphocyte associated protein 4 (Ctla4), Furin, lymphocyte activating 3 (Lag3), and programmed cell death 1 (Pdcd1) was upregulated in the KFCA model, compared with the KF (Figure 3I). Taken together, deletion of Arg1 in myeloid cells resulted in an increase in CD8+ T cell infiltration and activation, counterbalanced by an increase in exhaustion as well.

Figure 3
Download asset Open asset
Arginase 1 deletion in myeloid cells increases CD8+ T cell infiltration and activation in a spontaneous pancreatic ductal adenocarcinoma mouse model.

(A) Representative images of CD8 immunohistochemistry staining (brown) in KF and KFCA tissue. Scale bar, 50 μm. Quantification of positive area on the right, n=5–6/group. Student’s t test was used to determine statistical significance. (B) Uniform manifold approximation and projection (UMAP) visualization of defined T and natural killer (NK) cell clusters comparing single-cell RNA sequencing (sc-RNA-seq) data from KF and KFCA. (C) Dot plot of lineage markers used to identify the different types of lymphocytes. Dot size shows expression frequency, dot color shows average expression. (D) Pie charts showing the proportion of the identified lymphocyte populations in KF and KFCA sc-RNA-seq, percentage values are provided for populations that differ dramatically between KF and KFCA. (E) Table showing the percentage of each identified lymphocyte population in KF and KFCA sc-RNA-seq. (F) Violin plots showing normalized expression levels of T cell activation markers in all CD8+ T cell populations identified in KF and KFCA sc-RNA-seq data. (G) Representative images of co-immunofluorescence staining for CD8 (green), GZMB (red), CK19 (gray), and DAPI (blue). Scale bar, 100 μm. (H) Quantification of CD8+ GZMB+ cells, n=3/group. Student’s t test was used to determine significance. (I) Violin plots showing normalized expression levels of T cell exhaustion markers in all CD8+ T cell populations identified in KF and KFCA.

Figure 3—source data 1

Single cell population levels used to calculate the percentage of lymphocytes in KF and KFCA.

https://cdn.elifesciences.org/articles/80721/elife-80721-fig3-data1-v2.xlsx

Systemic arginase inhibition in combination with anti-PD1 immune checkpoint reduces tumor growth

Our genetic model revealed that deletion of Arg1 in myeloid cells reduced PanIN/PDA progression and was accompanied by an increased infiltration of CD8+ T cells. However, we also observed several compensatory mechanisms that may have blunted the effect of Arg1 loss. These included expression of Arg2 in myeloid cells and expression of Arg1 in epithelial cells. We reasoned that systemic inhibition of arginase (Steggerda et al., 2017), using a pharmacologic approach might bypass these compensatory mechanisms.

We implanted a KPC pancreatic cancer cell line (7940B) (Long et al., 2016) orthotopically into the pancreas of syngeneic C57BL6/J mice. Upon tumor detection (by palpation or by ultrasound), we randomly divided the mice into two groups to receive either vehicle or Arginase inhibitor (CB-1158, Calithera Biosciences) (Figure 4A). We pharmacologically treated the mice for 10 d and then harvested the tumors 20 d post-implantation. First, we investigated the infiltration of CD8+ T cells by staining the vehicle and CB-1158 mouse tissue for CD8 by immunohistochemistry . Interestingly, we observed that systemic inhibition of Arginase by CB-1158 increased the infiltration of CD8+ T cells (Figure 4B and C), recapitulating our findings from the genetically engineered model. To identify whether there was an increase in CD8+ T cell activation, we stained the tissue samples for CD8 and the activation marker GZMB, as well as the epithelial marker ECAD. While in the control tissue, GZMB expression was rare, in the CB-1158 treatment group, GZMB was common in CD8+ T cells (Figure 4D and E).

Figure 4 with 2 supplements see all
Download asset Open asset
Systemic inhibition of arginase by CB-1158 in combination with anti-PD1 reduces tumor growth in an orthotopic pancreatic ductal adenocarcinoma mouse model.

(A) Experimental timeline and design for orthotopic transplantation of 7940B KPC cells in syngeneic mice. (B) Representative images of immunohistochemistry staining for CD8 (brown). Scale bar, 50 μm. (C) Quantification of positive area of CD8 staining from B. Statistical significance was determined using unpaired t-test with Welch’s correction. (D) Representative images of co-immunofluorescence staining for CD8 (green), GZMB (red), ECAD (purple), and DAPI (blue) in the vehicle and CB-1158 treated group. Scale bar, 20 μm. White arrows point to co-localization of CD8 (green) with GZMB (red). (E) Percentage of CD8+ and GZMB+ cells. Statistical significance was determined using unpaired t-test with Welch’s correction. (F) Experimental timeline and design for orthotopic transplantation of 7940B KPC cells in syngeneic mice and different treatment groups. (G) Final tumor weight (mg) from the different treatment groups, n=10–12/group. Statistical significance was determined using two-way ANOVA with Tukey’s multiple comparisons correction test. (H) Metabolomic analysis showing relative arginine levels in the tumors of the different treatment groups. Two-way ANOVA was used to determine statistical significance, n=5–6/group. (I) Experimental scheme for CD8+ T cell isolation and growth in different media conditions. −Arg RPMI = RPMI lacking arginine, Orn = ornithine. (J) Percent of proliferated CD8+ T cells from flow cytometry analysis. (K) Percent of activated CD8+ T cells (CD44) from flow cytometry analysis. Two-way ANOVA with Tukey’s multiple comparisons correction test was used to determine significance. n=3/condition.

Data from the genetic model showed an increase in T cell activation but also an increase in exhaustion. We thus repeated the syngeneic orthotopic transplantation experiment described above, but this time we added blockade of the PD1 immune checkpoint to circumvent T cell exhaustion. Tumor bearing mice were divided into four different groups to receive: (1) vehicle + IgG control, (2) arginase inhibitor (CB-1158) + IgG, (3) vehicle + anti-PD1, and (4) CB-1158 + anti-PD1 (Figure 4F). We observed a trending decrease in tumor weight in the CB-1158 + IgG group and a significant decrease in tumor weight in the combination group of CB-1158 + anti-PD1 immune checkpoint blockade compared with our vehicle control group (Figure 4G). These findings recapitulated the decrease in tumor formation observed in the KFCA mouse model.

We then proceeded to characterize the tumor tissue. We examined ARG1 expression in macrophages (F4/80+) and epithelial (ECAD+) cells by co-immunofluorescence staining and observed no changes in ARG1 distribution or expression among treatment groups (Figure 4—figure supplement 1A), consistent with the notion that the CB-1158 Arginase inhibitor does not affect enzyme production but suppresses its activity. Hematoxylin and eosin (H&E) staining showed large necrotic areas in both CB-1158 and CB-1158 + anti-PD1 groups (Figure 4—figure supplement 1B). To further characterize the tumor tissue, we stained for cell proliferation (Ki67) and apoptotic cell death (CC3) by immunohistochemistry staining (Figure 4—figure supplement 1C and D). The combination treatment group showed a significant decrease in cell proliferation compared to the vehicle control group (Figure 4—figure supplement 1C and E). We also observed either a significant or trending increase in CC3 upon CB-1158 + IgG, vehicle + anti-PD1, or the combination treatment (Figure 4—figure supplement 1D and F). Additionally, metabolomics analysis of these orthotopic tumors revealed an increase in arginine levels in the tumors from mice treated with CB-1158 and anti-PD1 (Figure 4H).

Arginase breaks down arginine into urea and ornithine. Thus, it is equally conceivable that lack of arginine (Arg) or excess of ornithine (Orn) and/or urea might impair the ability of CD8+ T cells to proliferate and/or become activated. To determine how loss of Arginase increases CD8+ T cell proliferation and activation, we performed an in vitro CD8+ T cell proliferation and activation assay. We isolated naïve CD8+ T cells from spleen and lymph nodes of C57BL/6 mice and cultured them for 72 hr with complete RPMI media or with media lacking arginine (−Arg RPMI). In both media conditions, we added groups where the media was supplemented with either ornithine or urea, or with a combination of both (Figure 4I). We found that arginine deprivation results in reduced CD8+ T cell proliferation and activation (Figure 4J and K). Additionally, we found that culturing cells in RPMI media containing urea sightly enhanced CD8+ T cell proliferation and activation, compared to RPMI media control (Figure 4J and K, gray bars), while no enhancement was observed with ornithine supplementation.

When cells were cultured in RPMI media lacking arginine, supplementation with ornithine, but not urea, partially rescued the proliferation defect caused by lack of arginine. No further rescue occurred adding urea; neither ornithine nor urea rescued the activation defect caused by lack of arginine. We thus concluded that CD8+ T cells require arginine for proliferation and activation, and that the arginine breakdown byproducts are not harmful to CD8+ T cell proliferation nor are they able to fully rescue lack of arginine.

Together, these findings indicate that Arginase inhibition in combination with anti-PD1 reduces immune suppression and decreases pancreatic cancer tumor growth (see working model in Figure 5).

Figure 5
Download asset Open asset
Diagram depicting our working model.

(A) In pancreatic ductal adenocarcinoma (PDA), expression of Arg1 in myeloid cells is immune suppressive. (B) Deletion of Arg1 in myeloid cells in a spontaneous PDA mouse model induces macrophage repolarization and decreases tumor formation. (C) Systemic Arginase inhibition in combination with anti-PD1 immune checkpoint blockade further decreases tumor growth.

Discussion

Abundant myeloid cells in the TME are associated with poor prognosis in multiple types of cancer, including PDA (Gentles et al., 2015; Sanford et al., 2013; Tsujikawa et al., 2017). In contrast, high levels of T cells correlate with longer survival (Gentles et al., 2015; Balachandran et al., 2017). We and others have shown that myeloid cells promote pancreatic cancer growth both directly and by inhibiting CD8+ T cell anti-tumor immunity (Zhang et al., 2017b; Zhang et al., 2017a; Mitchem et al., 2013; Halbrook et al., 2019; Steele et al., 2016; Liou et al., 2015). The specific mechanisms by which macrophages drive immune suppression, and how to best target macrophages to improve outcomes in pancreatic cancer remain poorly understood.

Macrophages are plastic cell types, traditionally classified into pro-inflammatory ‘M1’ and anti-inflammatory ‘M2’ subtypes, based on their gene expression pattern (Mantovani et al., 2002). Recently, a wealth of evidence now supports the notion that TAMs are distinct from M1 and M2 (Boyer et al., 2022; DeNardo and Ruffell, 2019; Halbrook et al., 2019). Adding further complexity, TAMs also exhibit heterogeneous populations within an individual tumor. ARG1 is classically considered a ‘marker’ of the anti-inflammatory M2 state. In this study, we show that Arg1 is expressed in human and mouse TAMs, as well as in other myeloid populations. Furthermore, when we stratified human PDA based on ARG1 expression, we found inverse correlations between ARG1 and survival. However, prior to this work, a functional role of Arg1 in pancreatic TAMs and tumor immunity had not been evaluated.

Arginases are enzymes that hydrolyze the amino acid L-arginine to urea and L-ornithine in the liver urea cycle (Jenkinson et al., 1996). An analysis of plasma metabolites and tumor interstitial fluid in an autochthonous PDA mouse model revealed that L-arginine was drastically reduced in the tumor interstitial fluid (Sullivan et al., 2019). Additionally, ornithine levels increased in the PDA tumor interstitial fluid compared to plasma (Sullivan et al., 2019), suggesting arginase contribution to immunosuppression through depletion of arginine.

There are two isoforms of arginase, ARG1 and ARG2, located in the cytoplasm and mitochondria, respectively (Gotoh et al., 1996; Munder et al., 2005). The arginase genes share a 58% sequence identity (Haraguchi et al., 1987) and are almost identical at the catalytic site. Arg1 is normally expressed by hepatocytes, but it is also expressed in TAMs in a variety of tumor types. Arg2 is located in various cell types, including renal cells, neurons, and macrophages (Bronte and Zanovello, 2005; Caldwell et al., 2018). In a mouse model of Lewis lung carcinoma, myeloid cells express high levels of Arg1, resulting in impaired T cell function (Rodriguez et al., 2004). In that study, 3LL tumor cells were implanted subcutaneously in the right flank of the mice, and at the same time, mice were treated with the pan-arginase inhibitor tool compound N-hydroxy-nor-L-Arg. Arginase inhibition reduced subcutaneous tumor growth in a dose-dependent manner. The anti-tumor effect of the arginase inhibitor was in part dependent on T cell function, as inhibition on tumor growth was not observed when mice lacking a functional immune system were treated with the arginase inhibitor (Rodriguez et al., 2004). In another study (Miret et al., 2019), inhibition of arginase activity by the arginase inhibitor tool compound Cpd9 (Van Zandt et al., 2013) decreased T cell suppression and reduced tumor growth in a KrasG12D lung cancer mouse model. In a more recent study using a mouse model of neuroblastoma, myeloid Arg1 expression promoted tumor growth (Van de Velde et al., 2021).

To address the role of macrophage ARG1 in PDA, we used a dual-recombinase genetic approach to delete Arg1 in myeloid cells and aged the mice until most animals in the control group developed invasive PDA. We discovered that deletion of Arg1 in myeloid cells reduced progression to invasive disease, conversely resulting in accumulation of early lesions with prominent Tuft cells, a cell type that is protective toward tumor progression (DelGiorno et al., 2020; Hoffman et al., 2021). Reduced tumor progression was accompanied by changes in the immune microenvironment, such as an increase in infiltration and activation of CD8+ T cells. However, a fraction of the mice developed invasive disease. Complete CD8+ T cell reactivation against tumors did not occur as we also observed an increase in exhausted CD8+ T cells. Additionally, from sc-RNA-seq, we observed increased Arg2 expression in myeloid cells. This finding is in line with a report in which patients with ARG1 deficiency had an increase in ARG2 levels (Crombez and Cederbaum, 2005; Grody et al., 1993), suggesting compensation of ARG2 for the loss of ARG1.

Further analysis revealed that, in the absence of myeloid Arg1, the chemosensory tuft cells began to express ARG1. Tuft cells sense their surrounding environment and respond in a variety of ways, including modifying immune responses in a way that restrains PDA malignant progression (DelGiorno et al., 2020; Hoffman et al., 2021). Their compensation for the loss of myeloid Arg1 expression in what is likely now an arginine-rich microenvironment is consistent with these functions and suggests that systemic inhibition of ARG1 may have a more profound effect than its ablation from myeloid cells alone.

To systemically inhibit ARG1, we used CB-1158 (INCB001158), an orally bio-available small molecule inhibitor of arginase. CB-1158 is not cell permeable and thus does not inhibit liver ARG1, which would lead to immediate toxicity (Steggerda et al., 2017). In vitro, CB-1158 inhibits human recombinant ARG1 and ARG2. The in vivo action is attributed to inhibition of extracellular ARG1 released by TAMs and other myeloid cells (Steggerda et al., 2017). We used a syngeneic, orthotopic transplantation model based on KPC pancreatic cancer cells transplanted in C57Bl6/J mice (Hingorani et al., 2005; Long et al., 2016). Treatment with CB-1158 led to an increase in infiltrating CD8+ T cells, recapitulating the findings in the spontaneous model. Immune checkpoint therapies such as PD-1/PD-L1 used to enhance the anti-tumor immune response of T cells are not effective in pancreatic cancer (Brahmer et al., 2012), in part due to resistance mechanisms induced by myeloid cells. We found that the combination treatment of CB-1158 with anti-PD1 immune checkpoint blockade reactivated exhausted CD8+ T cells and decreased tumor growth. CB-1158 is currently evaluated as a single agent and in combination with immune checkpoint therapy or chemotherapy in patients with solid tumors (https://www.clinicaltrials.gov/, NCT02903914 and NCT03314935). An open question is whether the inhibitor also has a direct effect on epithelial cells. In a model of obesity-driven pancreatic cancer, Arg2 is upregulated in epithelial cells, and its knockdown reduces tumor growth in a cell autonomous manner, independently from immune responses (Zaytouni et al., 2017). While we did not observe Arg2 expression in epithelial cells in non-obese KF mice, analysis of human data revealed low, but detectable expression of Arg2, possibly supporting the possibility that, in human patients, CB-1158 might work through systemic inhibition of both arginase isoforms in multiple cell compartments, including epithelial cells.

Because of the heterogeneity of myeloid cells acquired by their interaction with the TME, myeloid cells most likely utilize multiple mechanisms that affect their function. Our findings show that one of the mechanisms by which myeloid cells promote immune suppression and tumor growth in pancreatic cancer is through overexpression and activity of Arg1. Thus, arginase inhibition may be an effective therapeutic strategy to enhance anti-tumor immune responses.

Materials and methods

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Strain, strain background (Mus musculus)C57BL/6 JJackson LaboratoryStock #: 000664
Strain, strain background (M. musculus)Arg1f/fJackson LaboratoryStock #: 008817
Strain, strain background (M. musculus)KFWen et al., 2019
Strain, strain background (M. musculus)KFCAThis paperPasca di Magliano Lab, University of Michigan
Cell line (M. musculus)7940BLong et al., 2016KPC cell line
AntibodyARG1 (Rabbit, monoclonal)Cell Signaling, Danvers, MACat #: 93668 SIF: 1:75
WB: 1:1000
AntibodyCD45 (Mouse, monoclonal)R&D Systems, Minneapolis, MNCat #: MAB14302IF: 1:400
AntibodyECAD (Mouse, monoclonal)Cell Signaling, Danvers, MACat #: 14472 SIF: 1:50
AntibodyF4/80 (Rabbit, monoclonal)Cell Signaling, Danvers, MACat #: 70076 SIF: 1:250
IHC: 1:250
AntibodyCK19, Troma III (Rat, monoclonal)Developmental Studies Hybridoma Bank, Iowa City, IAIF: 1:50
AntibodyKi67 (Rabbit, polyclonal)Abcam, Cambridge, UKCat #: ab15580IHC: 1:1000
AntibodyCC3 (Rabbit, polyclonal)Cell Signaling, Danvers, MACat #: 9661 LIHC: 1:300
AntibodyCD8 (Rabbit, monoclonal)Cell Signaling, Danvers, MACat #: 98941 SIHC: 1:300
IF: 1:400
AntibodyAPOE (Rabbit, monoclonal)AbcamCat #: ab183597IF: 1:500
AntibodyCOX1 (Goat, polyclonal)Santa CruzCat #:
Sc-1754		IF: 1:200
AntibodyGZMB (Rabbit, monoclonal)Cell signalingCat #: D2H2FIF: 1:800
AntibodyVinculin (Rabbit, monoclonal)Cell signalingCat #: 13901 SWB: 1:1000
Commercial assay, kitAlexa fluor 488 Tyramide SuperBoost kitInvitrogenCat #:
B40922
Commercial assay, kitRNA Scope Multiplex Fluorescent v2 Detection KitAdvanced Cell DiagnosticsCat #:
323110
Commercial assay, kitRNAscope Probe-Hs-ARG1Advanced Cell DiagnosticsCat #:
401581
Chemical compound, drugCB-1158Calithera Biosciences, Inc, South San Francisco, CA100 mg/kg,
Oral gavage, twice a day
Chemical compound, drugAnti-PD1BioXcellCat #:
BE0033-2, clone J43		200 μg/i.p.
Every 3 d
Software, algorithmR StudioRstudio.comVersion: 4.1.1 -- "Kick Things"
Software, algorithmImageJImagej.nih.govVersion: 2.0.0-rc-69/1.52 p
Software, algorithmAdobe IllustratorAdobe.com2022
Software, algorithmHalo softwareIndica Labs
Software, algorithmPrism 9 for macOSGraphpad.comVersion: 9.4.1 (458), July 18, 2022

Mice studies

Request a detailed protocol

Arg1f/f mice (Stock # 008817) and C57BL/6 J WT mice (Stock# 000664) were obtained from the Jackson Laboratory and bred in-house. Arg1f/f mice were generated to have loxP sites flanking exons 7 and 8 in the Arg1 gene (El Kasmi et al., 2008). Lyz2Cre/+ mice and KF (KrasFrt-STOP-Frt-G12D/+;Ptf1aFlpO/+) mice were donated by Dr. Howard Crawford. Lyz2Cre/+ mice express Cre in myeloid cells due to the insertion of the Cre cDNA into the endogenous M lysozyme (LysM) locus (Clausen et al., 1999). Lyz2Cre/+;Arg1f/f mice were generated by crossing Lyz2Cre/+ mice with Arg1f/f mice. KFCA mice were generated by crossing KF mice with Lyz2Cre/+;Arg1f/f mice. Age matched male and female mice were used in these studies.

Orthotopic surgery procedure

Request a detailed protocol

50 μl of 50,000 7940B cells (C57BL/6 J) resuspended in a 1:1 ratio of RPMI medium 1640 (Gibco, 11875093) and Matrigel matrix basement membrane (Corning, 354234) were injected into the pancreas of C57BL/6 J mice. For surgery procedure, see Aiello et al., 2016. 7940B cells were derived from a male KPC (KrasLSL-G12D/+;p53LSL-R172H/+;Ptf1aCre/+) mouse tumor (Long et al., 2016). Cells were tested for mycoplasma by MycoAlertTM Plus Mycoplasma Detection Kit (Lonza). Once mice had established tumors, around day 10 after implantation, mice were randomized into different treatment groups.

Chemical compounds

Request a detailed protocol

Arginase inhibitor, CB-1158 was synthesized and provided by Calithera Biosciences, Inc, South San Francisco, CA (2017). For the mice studies, CB-1158 was dissolved in Milli-Q water and administered by oral gavage twice a day at 100 mg/kg. This treatment started 10 d after tumor implantation and lasted for 10 d. The control group received Milli-Q water by oral gavage, twice a day. Purified anti-mouse PD1 antibody (BioXcell #BE0033-2, clone J43) was used for the in-vivo anti-PD1 blockade experiments. Anti-PD1 was used at a dose of 200  μg/i.p. injection, every 3 d. The control group received Polyclonal Armenian hamster IgG (BioXcell, BE0091), and it was administered in parallel to anti-PD1.

Single-cell RNA-seq

Request a detailed protocol

Human sc-RNA-seq data were previously published in Steele et al., 2020 (NIH dbGaP database accession #phs002071.v1.p1). Healthy mouse pancreas sc-RNA-seq data were previously published in Kemp et al., 2021b (NIH dbGap database accession #GSM5011581), and mouse spontaneous PDA sc-RNA-seq data generated using the KPC (KrasLSL-G12D/+;p53LSL-R172H/+;Ptf1aCre/+) model was previously published (NIH dbGap databse accession GSE202651). To generate the KF and KFCA sc-RNA-seq data, pancreatic tissue was harvested from KF (n=1) and KFCA mice (n=1) at 11 mo of age. The tissue was mechanically minced, then digested with Collagenase V (Sigma C9263, 1 mg/ml in RPMI) for 30 min at 37°C with shaking. Digestions were filtered through 500 μm, 100 μm, and 40 μm mesh to obtain single cells. Dead cells were removed using the MACS Dead Cell Removal Kit (Miltenyi Biotec). Single-cell complementary DNA libraries were prepared and sequenced at the University of Michigan Advanced Genomics Core using the 10× Genomics Platform. Samples were run using 50-cycle paired-end reads on the NovaSeq 6000 (Illumina) to a depth of 100,000 reads. The raw data were processed and aligned by the University of Michigan Advanced Genomics Core. Cell Ranger count version 4.0.0 was used with default settings, with an initial expected cell count of 10,000. Downstream sc-RNA-seq analysis was performed using R version 4.0.3, R package Seurat version 4.0.2, and R package SeuratObject version 4.0.1 (RStudio Team RStudio: Integrated Development for R [RStudio, 2015]); http://www.rstudio.com/ R Core Development Team R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2017); https://www.R-project.org/ (Butler et al., 2018; Stuart et al., 2019). Data were filtered to only include cells with at least 100 genes and genes that appeared in more than 3 cells. Data were normalized using the NormalizeData function with a scale factor of 10,000 and the LogNormalize normalization method. Data were then manually filtered to exclude cells with <1000 or >60,000 transcripts and <15% mitochondrial genes. Variable genes were identified using the FindVariableFeatures function. Data were scaled and centered using linear regression of transcript counts. PCA was run with the RunPCA function using the previously defined variable genes. Cell clusters were identified via the FindNeighbors and FindClusters functions, using dimensions corresponding to approximately 90% variance as defined by PCA. UMAP clustering algorithms were performed with RunUMAP. Clusters were defined by user-defined criteria. The complete R script including figure-specific visualization methods is publicly available on GitHub (https://github.com/PascaDiMagliano-Lab/Arginase-1-is-a-key-driver-of-immune-suppression-in-pancreatic-cancer, copy archived at swh:1:rev:ddd8595b93230f76ebc219588953cd36f4941572; Donahue, 2023).

Kaplan-Meier survival analysis

Request a detailed protocol

For Kaplan-Meier overall survival, we used the human dataset GSE71729 containing 125 primary PDA tumor samples. The samples were split into ARG1-low (n=62) and ARG1-high (n=63) groups. Survival analysis with log-ranked test was subsequently plotted in GraphPad Prism v9.

Histopathology

Request a detailed protocol

Tissues were fixed in 10% neutral-buffered formalin overnight, dehydrated, paraffin-embedded, and sectioned into slides. H&E and Gomori’s Trichrome staining were performed according to the manufacturer’s guidelines.

Immunohistochemistry (IHC)

Request a detailed protocol

Paraffin sections were re-hydrated with two series of xylene, two series of 100% ethanol, and two series of 95% ethanol. Slides were rinsed with water to remove previous residues. CITRA Plus (BioGenex) was used for antigen retrieval and microwaved for 5 min and then 3 min. Once cool down, sections were blocked with 1% bovine serum albumin (BSA) in PBS for 30 min. Primary antibodies were used at their corresponding dilutions (Key resources table) and incubated at 4°C overnight. Biotinylated secondary antibodies were used at a 1:300 dilution and applied to sections for 45 minat room temperature (RT). Sections were then incubated for 30 min with ABC reagent from Vectastain Elite ABC Kit (Peroxidase), followed by DAB (Vector).

Co-immunofluorescence (Co-IF)

Request a detailed protocol

Deparaffinized slides were blocked with 1% BSA in PBS for 1 hr at RT. Primary antibodies (Key resources table) were diluted in blocking buffer and incubated overnight at 4°C, followed by secondary antibody (Alexa Fluor secondaries, 1:300) for 45 min at RT. Slides were mounted with Prolong Diamond Antifade Mountant with DAPI (Invitrogen). TSA Plus Fluorescein (PerkinElmer) was also used in the Co-IF for primary antibodies.

In situ hybridization (ISH) with Co-IF

Request a detailed protocol

The RNA Scope Multiplex Fluorescent Detection Kit (Advanced Cell Diagnostics) was used according to the manufacturer’s protocol. The probe used for ARG1 was Hs-ARG1 (401581, Advanced Cell Diagnostics). Freshly cut human paraffin-embedded sections were baked for 1 hr at 60°C prior to staining. Slides were then deparaffinized and treated with hydrogen peroxide for 10 min at RT. Target retrieval was performed in a water steamer boiling for 15 min, and then slides were treated with the ProteasePlus Reagent (Advanced Cell Diagnostics) for 30 min. The RNA scope probe was hybridized for 2 hr at 40°C. The signal was amplified using the AMP (amplification) materials provided in the ACD Multiplex Kit (Advanced Cell Diagnostics). The signal was developed with horseradish peroxidase (HRP) channel. Once completed, the samples were washed in PBS, and then blocked for 1 hr with 5% donkey serum at RT. Primary antibody against CD45 (1:400) was incubated overnight at 4°C. Secondary antibodies (1:300 in blocking buffer) were incubated for 1 hr at RT, and samples were washed three times in PBS. Slides were counterstained with DAPI and mounted with ProLong Gold Antifade Mountant (Thermo Fisher Scientific).

Images were taken either with an Olympus BX53 microscope, a Leica SP5 microscope, a Leica STELLARIS 8 FALCON Confocal Microscopy System, or scanned with a Pannoramic SCAN scanner (Perkin Elmer). Quantification of positive cell number or area was done using ImageJ, three to five images/slide (200× or 400× magnification) taken from three to four samples per group or using the Halo software (Indica Labs).

Cell culture

Request a detailed protocol

The 7940B cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 11965–092) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin streptomycin. Tumor cell CM were collected from the 7940B cells that were cultured to confluency. Media were centrifuged at 300 g for 10 min at 4°C to remove contaminating tumor cells. These CM were used for the macrophage polarization assay. For macrophage polarization, BM cells were isolated from WT or Lyz2Cre/+;Arg1f/f mice femurs. Once isolated, BM cells were cultured with 7940B cell CM plus total DMEM media at a 1:1 ratio for 6 d. Fresh media were added during day 3. This process allowed the differentiation and polarization of BM cells to TAMs (Zhang et al., 2017a).

In vitro CD8 T cell culture

Request a detailed protocol

Naïve CD8 T cells were isolated from C57BL/6 mouse spleens and lymph nodes by magnetic bead separation (Miltenyi Biotec, cat # 130-096-543), following the manufacturers’ protocols. T cells were activated with plate-bound anti-CD3e (2 μg/ml) and soluble anti-CD28 (1 μg/ml) in the presence of mIL-2 (10 ng/ml; R&D Systems). Cells were cultured in media constituted with RPMI powder (USBiological, R9010-01) according to the manufacturer’s instructions and supplemented with 10% FBS and 50 μM 2-Mercaptoethanol (Gibco) or in RPMI medium lacking arginine (−Arg RPMI). 1.15 mM arginine was added to the RPMI medium. Ornithine (Orn) and urea were added at 1.15 mM to the corresponding media. 2 × 105 cells in 200 μL of media were plated in a flat-bottom 96-well plate and cultured for 3 d. To assess proliferation, cells were labeled with 5 μM Cell Trace Violet in 0.1% BSA/PBS for 30 min at 37°C prior to activation.

Western blot

Request a detailed protocol

TAMs from WT or Lyz2Cre/+;Arg1f/f mice were lysed in RIPA buffer (Sigma-Aldrich) with protease and phosphatase inhibitors (Sigma-Aldrich). Protein samples were quantified, normalized, and then electrophoresed in a 4–15% SDS-PAGE gel (BioRad). Protein was transferred to a PVDF (polyvinylidene difluoride) membrane (BioRad), blocked with 5% milk for 1 hr at RT, and then incubated with primary antibodies overnight at 4°C (Key resources table). Membranes were then incubated with HRP-conjugated secondary antibody (1:5000) for 2 hr at RT. Membranes were washed, incubated in Western Lightning Plus-ECL (PerkinElmer), and then visualized with the ChemiDoc Imaging System (BioRad).

Metabolomics analysis

Request a detailed protocol

CM (200 µL) was collected from each well of WT and Lyz2Cre/+;Arg1f/f TAMs in a six-well plate after 6 d of culture and used for extracellular metabolite profiling. Briefly, to the 200 µL of media, 800 µL of ice-cold 100% methanol was added. Cell lysates from parallel plates were used for protein quantification, and the protein amount was used to normalize the volume of samples collected for metabolomics. The samples were centrifuged at 12,000 g for 10 min after which the supernatant was collected, dried using SpeedVac Concentrator, reconstituted with 50% v/v methanol in water, and analyzed by targeted LC-MS/MS and processed as previously described (Nelson et al., 2020). For metabolomics in orthotopic tumors, ~50 mg of tumor tissue was grinded into powder with mortar and pestle containing liquid nitrogen. Thereafter, the samples were suspended in 1 mL of 80% methanol in a 1.5-mL Eppendorf tube and stored overnight at –80°C. Next day, samples were centrifuged at top speed, and supernatant was collected into a new 1.5-mL Eppendorf tube, dried, and processed for LC-MS/MS as with the in vitro samples.

Statistics

GraphPad Prism 9 was used to perform statistical analysis. T-test or ANOVA was performed for group comparisons. R software 3.5.2 was used for the analysis of the microarray data set. A p-value was considered statistically significant when p<0.05.

Data availability

Human sc-RNA-seq data was previously published (Steele et al., 2020) and both raw and processed data are available at the NIH dbGap database accession number phs002071.v1.p1. Raw and processed sc-RNA-seq data for the WT and KPC were previously published and are available at GEO accession number GSM5011580 and GSE202651. Raw and processed sc-RNA-seq data for the KF and KFCA are available at GEO accession number GSE203016.

The following data sets were generated
    1. di Magliano MP
    2. Menjivar RE
    3. Donahue KL
    (2022) NCBI Gene Expression Omnibus
    ID GSE203016. Arginase 1 deletion in myeloid cells decreases immune suppression and tumor formation in pancreatic cancer.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203016
The following previously published data sets were used
    1. di Magliano MP
    (2020) NCBI Gene Expression Omnibus
    ID GSE155698. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155698
    1. di Magliano MP
    2. Crawford HC
    3. Kemp SB
    (2021) NCBI Gene Expression Omnibus
    ID GSM5011580. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5011580

References

    1. Jenkinson CP
    2. Grody WW
    3. Cederbaum SD
    (1996) Comparative properties of arginases
    Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology 114:107–132.
    https://doi.org/10.1016/0305-0491(95)02138-8
    1. Singh R
    2. Pervin S
    3. Karimi A
    4. Cederbaum S
    5. Chaudhuri G
    (2000)
    Arginase activity in human breast cancer cell lines: N (omega) -hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells
    Cancer Research 60:3305–3312.

Decision letter

  1. Gina M DeNicola
    Reviewing Editor; Moffitt Cancer Center, United States
  2. Wafik S El-Deiry
    Senior Editor; Brown University, United States
  3. Gina M DeNicola
    Reviewer; Moffitt Cancer Center, United States

Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "Arginase 1 is a key driver of immune suppression in pancreatic cancer" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, including Gina M DeNicola as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Wafik El-Deiry as the Senior Editor.

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

1) Please tone down the language regarding Arg1 being previously used as merely a marker of macrophage identity. A general role for Arg1 and arginine metabolism by myeloid cells in immunosuppression has already been established by multiple studies, including those cited by the authors, in multiple tumor types. The authors should modify this text to avoid overstating their findings.

2) Please provide additional data or moderate other claims as indicated where they are not justified by the data presented. The claim that Arg1 deletion in macrophages delayed the formation of invasive disease is not completely justified by the data presented.

3) Please address reviewer points that require clarifications, and add quantifications where requested.

Reviewer #1 (Recommendations for the authors):

The authors should further support the claim that Arg1 deletion in macrophages delayed the formation of invasive disease, or moderate their language.

For the claim that Arg1 deletion in macrophages delayed the formation of invasive disease, ideally, more mice could be added to the cohort, but considering that it takes so long for the mice to develop tumors the authors could consider implanting the KPC 7940B line into LysMCre/+; Arg1fl/fl mice and performing a survival or time point analysis to further support this claim. Alternatively, they could perform this experiment with 7940B transplantation into BL6 mice and treat with the arginase inhibitor, then monitor the onset of PDAC.

Reviewer #2 (Recommendations for the authors):

Although this does not decrease the translational relevance of their findings, a main weakness of the manuscript is that the authors do not show what breaking down arginine and generating ornithine and urea does/is needed for metabolically to impact immunity, as no such metabolic assays or experiments are performed anywhere in their work.

1. It would therefore be best if the authors at least show that arginine breakdown is needed for CD8+ T cell activation and proliferation, as proposed/speculated.

A few additional comments:

2. CB-1158 inhibits both Arg1 and Arg2 as mentioned in the manuscript. Given that a metabolic role of tumor-cell specific Arg2 expression has previously been demonstrated in PDAC tumors, the observed anti-tumor CB-1158 effect could not be merely attributed to Arg1/Arg2 role in immunity, but also to tumor intrinsic effects of Arg2 on PDAC growth.

3. Figure 1A: ISH- co-IF staining data should be strengthened to support the claim; Zoomed in the photo shows 3 cells (yellow) that co-stain for ARG1(red) and CD45 (green). No quantification is provided. To support their claim "We observed prevalent ARG1 expression in CD45+ cells, and occasional low expression in ECAD+ cells", the authors should quantify the ISH/co-IF staining as done in other Figure 2 and its Supplement. It would be best if the authors could also show the individual fluorescence channels (prior to merging) in Supplementary data if they do not fit in the main figure.

4. The same comment as in point 3, i.e. quantify- for all other ISH-coIF figures, including Figure 1G; Figure Supplement 1E; Figure 2 Supplement 2H, and Figure 3G.

Reviewer #3 (Recommendations for the authors):

1. Mechanism of Arg1 upregulation in cancer cells: Inherent differences between spontaneous Kras-driven model and orthotopic Kras- p53-driven model should be discussed as a contextual backdrop for the potential role of Arg1. It is not clear from the data provided whether the determinant of Arg1 expression in cancer cells is driven by accumulating mutational burden (higher at baseline in aggressive KPC orthotopic model) vs time to progression as would be the case in many months that elapsed between PanIN and PDAC stages in KC model. Do orthotopic KPC lesions contain Tuft cells? Some quantification of data in Figure S4A may help as well.

2. Arginase 1 inhibitor activity in TME: are there changes in arginine levels in the TME of mice systemically treated with the inhibitor?

3. The authors should indicate in the main text the instances where the data shows the non-significant trend in PanIN frequency (ie. Figure S2C, page 16, line 316 currently described as 'decrease'); I would also strongly suggest making it clear that there are limitations with regards to sample size for scRNAseq analysis (one sample for each condition) and to take any conclusions that come with the description of said data with caution.

https://doi.org/10.7554/eLife.80721.sa1

Author response

Essential revisions:

1) Please tone down the language regarding Arg1 being previously used as merely a marker of macrophage identity. A general role for Arg1 and arginine metabolism by myeloid cells in immunosuppression has already been established by multiple studies, including those cited by the authors, in multiple tumor types. The authors should modify this text to avoid overstating their findings.

We have modified the text to better reflect our findings in the context of previous literature.

2) Please provide additional data or moderate other claims as indicated where they are not justified by the data presented. The claim that Arg1 deletion in macrophages delayed the formation of invasive disease is not completely justified by the data presented.

In our initial submission, we only had 12 mice for the KF group and 8 mice for the KFCA group, a limitation given the complexity of genotypes and the timeframe of the experiment (11-12 months). Several more mice were aging. In this resubmission, we include 26 and 24 mice, respectively; with the increase in animal numbers, our data indicating a delay in progression is substantiated. We have modified Figure 2E to reflect the new data as well as the related text on page 18.

3) Please address reviewer points that require clarifications, and add quantifications where requested.

We have amended the text for clarification and have included quantifications as requested by the reviewers. For Figures 1A and 1H, quantification is in Figure 1B and 1I, respectively. For Figure 2 Supplement 3D, quantification is in Figure 2 Supplement 3E. Quantification for Figure 3G is in Figure 3H.

Reviewer #1 (Recommendations for the authors):

The authors should further support the claim that Arg1 deletion in macrophages delayed the formation of invasive disease, or moderate their language.

For the claim that Arg1 deletion in macrophages delayed the formation of invasive disease, ideally, more mice could be added to the cohort, but considering that it takes so long for the mice to develop tumors the authors could consider implanting the KPC 7940B line into LysMCre/+; Arg1fl/fl mice and performing a survival or time point analysis to further support this claim. Alternatively, they could perform this experiment with 7940B transplantation into BL6 mice and treat with the arginase inhibitor, then monitor the onset of PDAC.

We thank reviewer 1 for these suggestions. Being aware that our initial numbers were small, we had been aging KF and KFCA mice to increase our cohorts. We now have 26 KF mice and 24 KFCA mice (compared with 12 and 8 previously). We have now included statistical analysis using Chi square test, showing statistical significance of the difference in tumor formation in the two cohorts (Figure 2E). Our results are consistent with the notion that deletion of Arginase 1 in myeloid cells decreases tumor formation in PDA.

Reviewer #2 (Recommendations for the authors):

Although this does not decrease the translational relevance of their findings, a main weakness of the manuscript is that the authors do not show what breaking down arginine and generating ornithine and urea does/is needed for metabolically to impact immunity, as no such metabolic assays or experiments are performed anywhere in their work.

1. It would therefore be best if the authors at least show that arginine breakdown is needed for CD8+ T cell activation and proliferation, as proposed/speculated.

Reviewer 2 raised a very important point, namely how, mechanistically, loss of Arginase increases T cell numbers in the tumor. Arginase breaks down arginine into ornithine and urea. Thus, it is equally conceivable that lack of arginine (Arg), or excess of ornithine (Orn) and/or urea, might impair the ability of CD8+ T cells to proliferate and/or become activated. In fact, a recent preprint from the Weaver group at UCSF (doi.org/10.1101/2022.07.14.499764) suggests that, in the context of breast cancer, Ornithine might directly impair T cell activation.

We designed the following experiment: we isolated Naive CD8+ T cells from spleens and lymph nodes of C57BL/6 mice and cultured them for 72 hrs with complete RPMI media or with media lacking arginine (-Arg RPMI). In both media conditions, we added groups where the media was supplemented with ornithine (Orn), with urea, or with a combination of ornithine and urea. We show that arginine deprivation results in reduced CD8 T cell proliferation and activation. We found that culturing cells in RPMI media containing urea slightly enhanced T cell proliferation and activation compared to RPMI media control, while no enhancement was observed with ornithine supplementation. When cells were cultured in RPMI media lacking arginine, supplementation with ornithine, but not urea, partially rescued the proliferation defect caused by lack of arginine. No further rescue occurred adding Urea; neither ornithine nor urea rescued the activation defect caused by lack of arginine. We thus concluded that CD8 T cell require arginine for proliferation and activation, and that the arginine breakdown byproducts are not harmful to CD8 T cell proliferation nor are they able to fully rescue lack of arginine. The new data is included the revised manuscript in Figure 4I, J, and K. Text describing these findings is included on page 32 and 33 of the revised manuscript.

A few additional comments:

2. CB-1158 inhibits both Arg1 and Arg2 as mentioned in the manuscript. Given that a metabolic role of tumor-cell specific Arg2 expression has previously been demonstrated in PDAC tumors, the observed anti-tumor CB-1158 effect could not be merely attributed to Arg1/Arg2 role in immunity, but also to tumor intrinsic effects of Arg2 on PDAC growth.

This is an important point. Arg2 is upregulated in obesity-driven PDA and silencing, or loss of Arg2 in PDA tumor cells suppressed tumor growth in obesity-associated PDA (Zaytouni et al., 2017). In our study, we found that the most highly expressed Arginase gene in both mouse and human PDA was Arg1 and not Arg2 (Figure 1). However, upon deletion of Arg1 in myeloid cells, we observed upregulation of Arg1 in epithelial cells and upregulation of Arg2 in a subset of macrophages, both likely compensatory mechanisms (Figure 2F and Figure 2—figure supplement 2A, and Figure 2I). Thus, it is also possible that the suppression in tumor growth upon treatment with the Arginase inhibitor is due to the systemic inhibition of both Arginase isoforms in multiple cell compartments, including epithelial cells. We have amended the text in the Discussion section on page 43 to acknowledge this possibility.

3. Figure 1A: ISH- co-IF staining data should be strengthened to support the claim; Zoomed in the photo shows 3 cells (yellow) that co-stain for ARG1(red) and CD45 (green). No quantification is provided. To support their claim "We observed prevalent ARG1 expression in CD45+ cells, and occasional low expression in ECAD+ cells", the authors should quantify the ISH/co-IF staining as done in other Figure 2 and its Supplement. It would be best if the authors could also show the individual fluorescence channels (prior to merging) in Supplementary data if they do not fit in the main figure.

We have now included quantification of the ARG1 RNA scope (in situ hybridization) in combination with immunofluorescence staining for CD45 and ECAD. We have also included the individual fluorescence channels as recommended by reviewer 2. This data supports the claim that there is prevalent ARG1 expression in CD45+ cells and occasional expression in ECAD+ cells. See Figure 1A and 1B.

4. The same comment as in point 3, i.e. quantify- for all other ISH-coIF figures, including Figure 1G; Figure Supplement 1E; Figure 2 Supplement 2H, and Figure 3G.

We have now added quantification to the immunofluorescent stainings. Figure 1G is now 1H. The quantification for Figure 1—figure supplement 1E is included in Figure 1I. Statistical significance was determined using a one-way ANOVA with multiple comparisons. The quantification for Figure 2 Supplement 2H, now Figure 2 Supplement 3D is shown in Figure 2 Supplement 2E, and the quantification for Figure 3G is shown in Figure 3H. Student’s t test was used to determine significance.

Reviewer #3 (Recommendations for the authors):

1. Mechanism of Arg1 upregulation in cancer cells: Inherent differences between spontaneous Kras-driven model and orthotopic Kras- p53-driven model should be discussed as a contextual backdrop for the potential role of Arg1. It is not clear from the data provided whether the determinant of Arg1 expression in cancer cells is driven by accumulating mutational burden (higher at baseline in aggressive KPC orthotopic model) vs time to progression as would be the case in many months that elapsed between PanIN and PDAC stages in KC model. Do orthotopic KPC lesions contain Tuft cells? Some quantification of data in Figure S4A may help as well.

Tuft cells emerge during early lesions as a response to injury, but progressively decrease in advanced PanINs and invasive PDA (Bailey et al., 2014; Delgiorno et al., 2014); thus, they are not found in orthotopic tumors; we clarified this in the text.

2. Arginase 1 inhibitor activity in TME: are there changes in arginine levels in the TME of mice systemically treated with the inhibitor?

We performed metabolomic analysis in the tumors treated with vehicle, arginase inhibitor, anti-PD1, and with the combination of arginase inhibitor and antiPD1 and observed a significant increase in arginine levels in the combination group. Data is shown in manuscript Figure 4H.

3. The authors should indicate in the main text the instances where the data shows the non-significant trend in PanIN frequency (ie. Figure S2C, page 16, line 316 currently described as 'decrease'); I would also strongly suggest making it clear that there are limitations with regards to sample size for scRNAseq analysis (one sample for each condition) and to take any conclusions that come with the description of said data with caution.

We have amended the text on page 16, (page 17 and page 18 in the revised manuscript) in agreement with the reviewer’s suggestions.

https://doi.org/10.7554/eLife.80721.sa2

Article and author information

Author details

  1. Rosa E Menjivar

    Cellular and Molecular Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Project administration
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1551-869X

  2. Zeribe C Nwosu

    Department of Molecular and Integrative Physiology, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Formal analysis, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  3. Wenting Du

    Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  4. Katelyn L Donahue

    Cancer Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Formal analysis
    Competing interests
    No competing interests declared

  5. Hanna S Hong

    Department of Immunology, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  6. Carlos Espinoza

    Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  7. Kristee Brown

    Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  8. Ashley Velez-Delgado

    Department of Cell and Developmental Biology, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  9. Wei Yan

    Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  10. Fatima Lima

    Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  11. Allison Bischoff

    Cancer Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5119-5272

  12. Padma Kadiyala

    Department of Immunology, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  13. Daniel Salas-Escabillas

    Cancer Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0819-989X

  14. Howard C Crawford

    Henry Ford Pancreatic Cancer Center, Detroit, United States
    Contribution
    Resources, Writing – review and editing
    Competing interests
    No competing interests declared

  15. Filip Bednar

    1. Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States
    2. Rogel Cancer Center, Ann Arbor, United States
    Contribution
    Supervision
    Competing interests
    No competing interests declared

  16. Eileen Carpenter

    1. Rogel Cancer Center, Ann Arbor, United States
    2. Department of Internal Medicine, Division of Gastroenterolog, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Formal analysis
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6775-6943

  17. Yaqing Zhang

    1. Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States
    2. Rogel Cancer Center, Ann Arbor, United States
    Contribution
    Supervision, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  18. Christopher J Halbrook

    1. Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, United States
    2. Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  19. Costas A Lyssiotis

    1. Department of Molecular and Integrative Physiology, University of Michigan-Ann Arbor, Ann Arbor, United States
    2. Cancer Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States
    3. Rogel Cancer Center, Ann Arbor, United States
    4. Department of Internal Medicine, Division of Gastroenterolog, University of Michigan-Ann Arbor, Ann Arbor, United States
    Contribution
    Resources, Supervision, Writing – review and editing
    For correspondence
    clyssiot@umich.edu
    Competing interests
    has received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics, and T-Knife Therapeutics, and is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-pathway as a therapeutic approach (US Patent No: 2015126580-A1, 05/07/2015; US Patent No: 20190136238, 05/09/2019; International Patent No: WO2013177426-A2, 04/23/2015)
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9309-6141

  20. Marina Pasca di Magliano

    1. Cellular and Molecular Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States
    2. Cancer Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States
    3. Department of Cell and Developmental Biology, University of Michigan-Ann Arbor, Ann Arbor, United States
    4. Henry Ford Pancreatic Cancer Center, Detroit, United States
    5. Rogel Cancer Center, Ann Arbor, United States
    Contribution
    Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing
    For correspondence
    marinapa@umich.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9632-9035

Funding

National Institutes of Health (T32-GM007315)

  • Rosa E Menjivar

National Cancer Institute (F31-CA257533)

  • Rosa E Menjivar

National Institutes of Health (T32-HD007505)

  • Rosa E Menjivar

University of Michigan (Rackham Merit Fellowship)

  • Rosa E Menjivar

American Cancer Society (Scholar grant)

  • Marina Pasca di Magliano

Pancreatic Cancer Action Network

  • Marina Pasca di Magliano

National Institutes of Health (U01-CA224145)

  • Marina Pasca di Magliano

National Institutes of Health (R01-CA151588)

  • Marina Pasca di Magliano

National Cancer Institute (R01-CA198074)

  • Marina Pasca di Magliano

National Cancer Institute (U01CA274154)

  • Marina Pasca di Magliano

National Cancer Institute (R01CA268426)

  • Marina Pasca di Magliano

National Cancer Institute (R37-CA237421)

  • Costas A Lyssiotis

National Cancer Institute (R01-CA248160)

  • Costas A Lyssiotis

National Cancer Institute (R01-CA244931)

  • Costas A Lyssiotis

National Cancer Institute (R01-CA247516)

  • Howard C Crawford

University of Michigan (Postdoctoral Pioneer Program)

  • Zeribe C Nwosu

University of Michigan (Training Program in Organogenesis)

  • Wenting Du

National Cancer Institute (T32-CA009676)

  • Katelyn L Donahue
  • Daniel Salas-Escabillas

National Cancer Institute (T32-AI007413)

  • Hanna S Hong

National Institute of Diabetes and Digestive and Kidney Diseases (T32-DK094775)

  • Hanna S Hong

National Cancer Institute (F31-CA247037)

  • Ashley Velez-Delgado

National Institute of General Medical Sciences (T32-GM008353)

  • Ashley Velez-Delgado

National Institutes of Health (T32-AI007413)

  • Padma Kadiyala

American College of Gastroenterology (T32-DK094775)

  • Eileen Carpenter

National Cancer Institute (R50-CA232985)

  • Yaqing Zhang

National Cancer Institute (F32-CA228328)

  • Christopher J Halbrook

National Institutes of Health (R00-CA241357)

  • Christopher J Halbrook

Sky Foundation

  • Christopher J Halbrook

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank Daniel Long and Michael Mattea for histology services at the University of Michigan. We thank Calithera Biosciences for providing the Arginase inhibitor, CB-1158. We thank the Advanced Genomics core at the University of Michigan for RNA sequencing. We also thank the Microscopy Core and the Flow Cytometry Core at the University of Michigan Biomedical Research Core Facilities for providing access to advanced microscopy and flow cytometry. We thank the Microscopy, Imaging and Cellular Physiology Core of the Michigan Diabetes Research Center at the University of Michigan for providing access to the Leica STELLARIS 8 FALCON Confocal Microscopy System, funded by grant NIH S10OD28612-01-A1. This study was supported by NIH/NCI U01CA224145, R01CA151588, R01CA198074, R01CA268426, U01CA274154, by an American Cancer Society Scholar grant and by the Pancreatic Cancer Action Network to M Pasca di Magliano. This study was also supported by the University of Michigan Cancer Center Support Grant (NCI P30CA046592), including an Administrative Supplement to M Pasca di Magliano. CA Lyssiotis was supported by the NCI (R37CA237421, R01CA248160, R01CA244931). HC Crawford was supported by R01 CA247516. RE Menjivar was supported by the University of Michigan Rackham Merit Fellowship, by the Cellular and Molecular Biology Training Grant (NIH T32-GM007315), by the Center for Organogenesis Training Program (NIH T32-HD007505), and by the NCI (F31-CA257533). ZC Nwosu was supported by the Michigan Postdoctoral Pioneer Program, University of Michigan Medical School. WD was supported by University of Michigan Training Program in Organogenesis. KL Donahue was supported by the Cancer Biology Program training grant (T32-CA009676). HSH was supported by 2T32AI007413 and T32DK094775. A Velez-Delgado was supported by the Rackham Merit Fellowship, by the Cellular Biotechnology Training Program (T32GM008353) and by the NCI (F31-CA247037). P Kadiyala was supported by the Immunology training grant (T32-AI007413). D Salas-Escabillas was supported by the Rackham Merit Fellowship and by the Cancer Biology Program training grant (T32-CA009676). ES Carpenter was supported by the American College of Gastroenterology Clinical Research Award and by T32-DK094775. Y Zhang was funded by the NCI-R50CA232985. CJ Halbrook was supported by F32CA228328, K99/R00CA241357, P30CA062203, and the Sky Foundation. The funders did not have a role in the planning, execution, or writing of this study.

Ethics

Human research was performed in accordance with the Declaration of Helsinki and the ethical standards and guidelines approved by the University of Michigan Institutional Review Board. Patients provided written informed consent.

All the animal studies and procedures were conducted in compliance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at the University of Michigan, protocol number: PRO00009814.

Senior Editor

  1. Wafik S El-Deiry, Brown University, United States

Reviewing Editor

  1. Gina M DeNicola, Moffitt Cancer Center, United States

Reviewer

  1. Gina M DeNicola, Moffitt Cancer Center, United States

Version history

  1. Received: June 1, 2022
  2. Preprint posted: June 24, 2022 (view preprint)
  3. Accepted: January 30, 2023
  4. Accepted Manuscript published: February 2, 2023 (version 1)
  5. Version of Record published: June 12, 2023 (version 2)

Copyright

© 2023, Menjivar et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,187
    Page views
  • 521
    Downloads
  • 7
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rosa E Menjivar
  2. Zeribe C Nwosu
  3. Wenting Du
  4. Katelyn L Donahue
  5. Hanna S Hong
  6. Carlos Espinoza
  7. Kristee Brown
  8. Ashley Velez-Delgado
  9. Wei Yan
  10. Fatima Lima
  11. Allison Bischoff
  12. Padma Kadiyala
  13. Daniel Salas-Escabillas
  14. Howard C Crawford
  15. Filip Bednar
  16. Eileen Carpenter
  17. Yaqing Zhang
  18. Christopher J Halbrook
  19. Costas A Lyssiotis
  20. Marina Pasca di Magliano
(2023)
Arginase 1 is a key driver of immune suppression in pancreatic cancer
eLife 12:e80721.
https://doi.org/10.7554/eLife.80721

Categories and tags

Research organisms

Further reading

    1. Biochemistry and Chemical Biology
    2. Cancer Biology

    Pancreatic tumors exhibit myeloid-driven amino acid stress and upregulate arginine biosynthesis

    Juan J Apiz Saab, Lindsey N Dzierozynski ... Alexander Muir
    Research Advance Updated

    Nutrient stress in the tumor microenvironment requires cancer cells to adopt adaptive metabolic programs for survival and proliferation. Therefore, knowledge of microenvironmental nutrient levels and how cancer cells cope with such nutrition is critical to understand the metabolism underpinning cancer cell biology. Previously, we performed quantitative metabolomics of the interstitial fluid (the local perfusate) of murine pancreatic ductal adenocarcinoma (PDAC) tumors to comprehensively characterize nutrient availability in the microenvironment of these tumors. Here, we develop Tumor Interstitial Fluid Medium (TIFM), a cell culture medium that contains nutrient levels representative of the PDAC microenvironment, enabling us to study PDAC metabolism ex vivo under physiological nutrient conditions. We show that PDAC cells cultured in TIFM adopt a cellular state closer to that of PDAC cells present in tumors compared to standard culture models. Further, using the TIFM model, we found arginine biosynthesis is active in PDAC and allows PDAC cells to maintain levels of this amino acid despite microenvironmental arginine depletion. We also show that myeloid derived arginase activity is largely responsible for the low levels of arginine in PDAC tumors. Altogether, these data indicate that nutrient availability in tumors is an important determinant of cancer cell metabolism and behavior, and cell culture models that incorporate physiological nutrient availability have improved fidelity to in vivo systems and enable the discovery of novel cancer metabolic phenotypes.

    1. Biochemistry and Chemical Biology
    2. Cancer Biology

    Cancer: How nearby nutrients shape tumor growth

    Nada Kalaany
    Insight

    Studying the nutrient composition immediately surrounding pancreatic cancer cells provides new insights into their metabolic properties and how they can evade the immune system to promote disease progression.

    1. Biochemistry and Chemical Biology
    2. Cancer Biology

    FOXP2 confers oncogenic effects in prostate cancer

    Xiaoquan Zhu, Chao Chen ... Yanyang Zhao
    Research Article Updated

    Identification oncogenes is fundamental to revealing the molecular basis of cancer. Here, we found that FOXP2 is overexpressed in human prostate cancer cells and prostate tumors, but its expression is absent in normal prostate epithelial cells and low in benign prostatic hyperplasia. FOXP2 is a FOX transcription factor family member and tightly associated with vocal development. To date, little is known regarding the link of FOXP2 to prostate cancer. We observed that high FOXP2 expression and frequent amplification are significantly associated with high Gleason score. Ectopic expression of FOXP2 induces malignant transformation of mouse NIH3T3 fibroblasts and human prostate epithelial cell RWPE-1. Conversely, FOXP2 knockdown suppresses the proliferation of prostate cancer cells. Transgenic overexpression of FOXP2 in the mouse prostate causes prostatic intraepithelial neoplasia. Overexpression of FOXP2 aberrantly activates oncogenic MET signaling and inhibition of MET signaling effectively reverts the FOXP2-induced oncogenic phenotype. CUT&Tag assay identified FOXP2-binding sites located in MET and its associated gene HGF. Additionally, the novel recurrent FOXP2-CPED1 fusion identified in prostate tumors results in high expression of truncated FOXP2, which exhibit a similar capacity for malignant transformation. Together, our data indicate that FOXP2 is involved in tumorigenicity of prostate.